{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"CUE-101"},{"type":"CodeName","name":"CUE101"},{"type":"CodeName","name":"CUE 101"},{"type":"Synonym","name":"anti-HPV16 E7 fusion protein CUE-101"}],"definition":{"html":"A fusion protein composed of a human leukocyte antigen (HLA) complex, HLA-A*0201, with a peptide epitope derived from the human papillomavirus type 16 (HPV16) E7 protein (amino acid residues 11-20), a reduced affinity human interleukin-2 (IL-2) variant, and an effector attenuated human immunoglobulin G1 (IgG1) Fc domain, with potential antineoplastic and immunostimulatory activities. Upon administration, CUE-101 targets and selectively binds to E7-specific CD8-positive T cells present in patients with HPV16-driven malignancies. This may induce the secretion of inflammatory cytokines such as interferon gamma (IFN gamma) and promote the activation and expansion of tumor-specific CD8-positive cells, which may lead to T-cell-mediated elimination of tumor cells expressing the HPV16 E7 antigen. The HPV16 E7 oncoprotein is a cell surface glycoprotein and tumor-associated antigen (TAA) that is overexpressed in various HPV-associated cancers.","text":"A fusion protein composed of a human leukocyte antigen (HLA) complex, HLA-A*0201, with a peptide epitope derived from the human papillomavirus type 16 (HPV16) E7 protein (amino acid residues 11-20), a reduced affinity human interleukin-2 (IL-2) variant, and an effector attenuated human immunoglobulin G1 (IgG1) Fc domain, with potential antineoplastic and immunostimulatory activities. Upon administration, CUE-101 targets and selectively binds to E7-specific CD8-positive T cells present in patients with HPV16-driven malignancies. This may induce the secretion of inflammatory cytokines such as interferon gamma (IFN gamma) and promote the activation and expansion of tumor-specific CD8-positive cells, which may lead to T-cell-mediated elimination of tumor cells expressing the HPV16 E7 antigen. The HPV16 E7 oncoprotein is a cell surface glycoprotein and tumor-associated antigen (TAA) that is overexpressed in various HPV-associated cancers."},"drugInfoSummaryLink":null,"nciConceptId":"C162459","nciConceptName":"HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101","termId":798742,"name":"HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc fusion protein CUE-101","firstLetter":"h","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"hpv16-e7-specific-hla-a0201-restricted-igg1-fc-fusion-protein-cue-101"}],"links":null}